Allergan Plc (AGN) 268.99 $AGN
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Open-Angle Glaucoma Pipeline Review, H2 2015 - 16 Companies & 21 Drug Profiles
M2 - Wed Oct 07, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55m6kn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aerie Pharmaceuticals, Inc. - Allergan Plc - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Oxford BioMedica Plc - Sanofi - Santen Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Sylentis S.A. - vTv Therapeutics LLC Drug Profiles - (carteolol hydrochloride latanoprost) - (dorzolamide hydrochloride latanoprost) - (latanoprost trabodenoson) - AMA-0076 - AR-13324 - ATS-8535 - bamosiran - bimatoprost SR - DE-117 - Glaucoma-GT - HPP-851 - latanoprost - latanoprost SR - latanoprostene bunod - ONO-9054 - OPA-6566 - RO-5093151 - SAR-366234 - Small Molecules to Antagonize CXCR3 for Glaucoma - trabodenoson - travoprost SR For more information visit http://www.researchandmarkets.com/research/55m6kn/openangle
AGN: 268.99 (-3.89), VTVT: 7.93 (+1.24), ITEK: 9.94 (+0.20), AERI: 21.25 (+2.35), OCUL: 15.44 (+0.79)
Acorda Soars, Settles Ampyra Patent Dispute with Allergan
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:00PM CDT
Acorda Therapeutics (ACOR) settles Ampyra patent litigation with Allergan; shares jump 12%.
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), TEVA: 58.55 (+0.58), ACOR: 29.94 (+0.23)
SmarTrend Watching for Potential Rebound in Shares of Allergan After 2.05% Loss
Comtex SmarTrend(R) - Tue Oct 06, 3:45PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $262.79 to a high of $282.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $266.09 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 268.99 (-3.89)
Allergan and Medicines360 Announces LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg IUS Presented in 3 Abstracts at FIGO 2015
PR Newswire - Tue Oct 06, 6:01AM CDT
Allergan plc (NYSE: AGN) and Medicines 360 today announced that LILETTA® will be featured in 3 abstracts presenting new data at the FIGO World Congress of Gynecology and Obstetrics, which takes place from October 4-9, 2015 in Vancouver, Canada.
AGN: 268.99 (-3.89)
3 Stocks with Strong Competitive Positions
Brian Feroldi, George Budwell, and Cheryl Swanson, The Motley Fool - Motley Fool - Mon Oct 05, 3:15PM CDT
Image Source: Pixel-Sepp via pixabay. The key to investing is not assessing how much an industry is going to affect society, or how much it will grow, but rather determining the competitive advantage of any given company and, above all, the...
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), PFE: 33.29 (+0.50)
Don’t Let Biosimilars Hold Off Your Pharma Stock Investments
Dana Blankenhorn - Amigobulls - Mon Oct 05, 9:21AM CDT
Don't Let Biosimilars Hold Off Your Pharma Stock Investments Because Of Biosimilars. The threat of biosimilars is as similar as Hillary, and no more real.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), NVS: 91.60 (-1.77)
Global Neisseria Gonorrhoeae Infections Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vp26fv/neisseria) has announced the addition of the "Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Allergan Plc - BioDiem Ltd - Biolytics Pharma - Debiopharm International S.A. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Sarepta Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Vertex Pharmaceuticals Incorporated Drug Profiles - Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Arenicin - BDM-I - Biologic for Neisseria Gonorrhoeae Infection - Cribrostatin-6 - dalbavancin - Debio-1453 - gepotidacin mesylate - gonorrhoeae vaccine - SM-295291 - SM-369926 - Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - VT-12008911 - zoliflodacin For more information visit http://www.researchandmarkets.com/research/vp26fv/neisseria
AGN: 268.99 (-3.89), VRTX: 109.40 (-0.06), SRPT: 37.97 (-0.03), GSK: 39.72 (-0.05)
WPZ, ETE, ETP, BIIB: Jim Cramer's Views
at The Street - Mon Oct 05, 12:00AM CDT
Jim Cramer shares his views on market psychology and making big money. Williams Partners, Energy Transfer Equity, Energy Transfer Partners and Biogen are among the stocks discussed here.
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), ETP: 45.34 (+1.58), ETE: 24.69 (+0.90), WPZ: 35.00 (+0.17)
Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices
at The Street - Fri Oct 02, 11:32AM CDT
Rising drug prices are getting increased scrutiny from lawmakers and presidential hopefuls, but here are nine stocks positioned well.
AGN: 268.99 (-3.89), ESRX: 82.57 (+1.27), VRTX: 109.40 (-0.06), WBA: 84.44 (+0.34), PFE: 33.29 (+0.50), ALXN: 164.78 (+4.78), CVS: 101.01 (+1.19), BMY: 60.55 (+0.67), ALKS: 59.98 (+1.48), MS: 32.93 (+0.57)
Pharma Deals in Latin America Continue, Teva to Buy Rimsa
Arpita Dutt - Zacks Investment Research - Fri Oct 02, 9:00AM CDT
Teva (TEVA) joins the league of health care companies expanding their presence in Latin America through acquisitions.
AGN: 268.99 (-3.89), ENDP: 63.14 (-0.96), MYL: 42.23 (-0.62), TEVA: 58.55 (+0.58)
Allergan and Humana Announce Research Partnership to Improve Health Outcomes
PR Newswire - Fri Oct 02, 7:30AM CDT
Allergan plc (NYSE: AGN), a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, to explore new ideas and ways to improve the health and well-being of patients, members and their caregivers.
AGN: 268.99 (-3.89), HUM: 180.92 (+2.02)
Urinary Incontinence - Pipeline Review, H2 2015
M2 - Fri Oct 02, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwlrf3/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Astellas Pharma Inc. - Celogos - Cook MyoSite Incorporated - Evotec AG - FemmePharma Global Healthcare, Inc. - Innovacell Biotechnologie AG - TheraVida, Inc. Drug Profiles - (mirabegron solifenacin succinate) - ASP-2205 - ASP-5633 - Cell Therapy for Urinary Incontinence - ICES-13 - oxybutynin hydrochloride - Prof-003 - RCD-1 - senrebotase - Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - THVD-201 - THVD-202 For more information visit http://www.researchandmarkets.com/research/jwlrf3/urinary
AGN: 268.99 (-3.89)
Allergan wins US FDA approval for JUVEDERM ULTRA XC for lip augmentation
M2 - Fri Oct 02, 6:01AM CDT
Pharmaceutical company Allergan (NYSE:AGN) disclosed on Thursday that it has received approval from the US Food and Drug Administration (FDA) to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21.
AGN: 268.99 (-3.89)
KYBELLA® Injection Wins Allure Magazine "Best of Beauty" Award
PR Newswire - Fri Oct 02, 6:01AM CDT
Allergan, plc (NYSE: AGN) is pleased to announce that KYBELLA® (deoxycholic acid) injection, the first and only FDA-approved injectable treatment for improving the appearance of moderate to severe submental fullness, also known as "double chin," received a "2015 Breakthrough Award" from Allure Magazine. The publication honored KYBELLA®, along with other winners from their annual "Best of Beauty" list, which included hundreds of luxury, mass market and specialty beauty and aesthetic brands, on September 21 at an awards ceremony held at One World Trade Center in New York.
AGN: 268.99 (-3.89)
Markets Close Mixed Ahead Of Jobs Report – Markets This Morning
Dana Blankenhorn - Amigobulls - Fri Oct 02, 5:22AM CDT
Markets closed mixed ahead of US jobs data. Biotech stock recovered from their earlier lows. Jobs data will dictate what happens markets this morning.
NFLX: 108.10 (-0.23), AGN: 268.99 (-3.89), AMZN: 541.94 (+4.46), NBIX: 38.93 (-1.07), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55), MSFT: 46.80 (+0.05), AAPL: 110.78 (-0.53), CELG: 116.98 (+4.79)
Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin
PR Newswire - Thu Oct 01, 8:10AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel prescription products for the medical aesthetics market. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion.
AGN: 268.99 (-3.89)
U.S. FDA Approves JUVEDERM® ULTRA XC for Use in Lips
PR Newswire - Thu Oct 01, 6:01AM CDT
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM® ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM® ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.
AGN: 268.99 (-3.89)
Allergan (AGN) Stock Spiked on Strong Revenue Projection
at The Street - Wed Sep 30, 3:52PM CDT
Allergan (AGN) shares closed trading up nearly 8% after the company updated its fiscal 2015 second half financial expectations.
AGN: 268.99 (-3.89), TEVA: 58.55 (+0.58)
This Is How Big Money Is Made
at The Street - Wed Sep 30, 2:27PM CDT
We lighten up on what we bought when we had courage.
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), ETP: 45.34 (+1.58)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Open-Angle Glaucoma Pipeline Review, H2 2015 - 16 Companies & 21 Drug Profiles
M2 - Wed Oct 07, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55m6kn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aerie Pharmaceuticals, Inc. - Allergan Plc - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Oxford BioMedica Plc - Sanofi - Santen Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Sylentis S.A. - vTv Therapeutics LLC Drug Profiles - (carteolol hydrochloride latanoprost) - (dorzolamide hydrochloride latanoprost) - (latanoprost trabodenoson) - AMA-0076 - AR-13324 - ATS-8535 - bamosiran - bimatoprost SR - DE-117 - Glaucoma-GT - HPP-851 - latanoprost - latanoprost SR - latanoprostene bunod - ONO-9054 - OPA-6566 - RO-5093151 - SAR-366234 - Small Molecules to Antagonize CXCR3 for Glaucoma - trabodenoson - travoprost SR For more information visit http://www.researchandmarkets.com/research/55m6kn/openangle
AGN: 268.99 (-3.89), VTVT: 7.93 (+1.24), ITEK: 9.94 (+0.20), AERI: 21.25 (+2.35), OCUL: 15.44 (+0.79)
Acorda Soars, Settles Ampyra Patent Dispute with Allergan
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:00PM CDT
Acorda Therapeutics (ACOR) settles Ampyra patent litigation with Allergan; shares jump 12%.
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), TEVA: 58.55 (+0.58), ACOR: 29.94 (+0.23)
SmarTrend Watching for Potential Rebound in Shares of Allergan After 2.05% Loss
Comtex SmarTrend(R) - Tue Oct 06, 3:45PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $262.79 to a high of $282.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $266.09 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 268.99 (-3.89)
Allergan and Medicines360 Announces LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg IUS Presented in 3 Abstracts at FIGO 2015
PR Newswire - Tue Oct 06, 6:01AM CDT
Allergan plc (NYSE: AGN) and Medicines 360 today announced that LILETTA® will be featured in 3 abstracts presenting new data at the FIGO World Congress of Gynecology and Obstetrics, which takes place from October 4-9, 2015 in Vancouver, Canada.
AGN: 268.99 (-3.89)
3 Stocks with Strong Competitive Positions
Brian Feroldi, George Budwell, and Cheryl Swanson, The Motley Fool - Motley Fool - Mon Oct 05, 3:15PM CDT
Image Source: Pixel-Sepp via pixabay. The key to investing is not assessing how much an industry is going to affect society, or how much it will grow, but rather determining the competitive advantage of any given company and, above all, the...
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), PFE: 33.29 (+0.50)
Don’t Let Biosimilars Hold Off Your Pharma Stock Investments
Dana Blankenhorn - Amigobulls - Mon Oct 05, 9:21AM CDT
Don't Let Biosimilars Hold Off Your Pharma Stock Investments Because Of Biosimilars. The threat of biosimilars is as similar as Hillary, and no more real.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), NVS: 91.60 (-1.77)
Global Neisseria Gonorrhoeae Infections Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vp26fv/neisseria) has announced the addition of the "Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Allergan Plc - BioDiem Ltd - Biolytics Pharma - Debiopharm International S.A. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Sarepta Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Vertex Pharmaceuticals Incorporated Drug Profiles - Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Arenicin - BDM-I - Biologic for Neisseria Gonorrhoeae Infection - Cribrostatin-6 - dalbavancin - Debio-1453 - gepotidacin mesylate - gonorrhoeae vaccine - SM-295291 - SM-369926 - Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - VT-12008911 - zoliflodacin For more information visit http://www.researchandmarkets.com/research/vp26fv/neisseria
AGN: 268.99 (-3.89), VRTX: 109.40 (-0.06), SRPT: 37.97 (-0.03), GSK: 39.72 (-0.05)
WPZ, ETE, ETP, BIIB: Jim Cramer's Views
at The Street - Mon Oct 05, 12:00AM CDT
Jim Cramer shares his views on market psychology and making big money. Williams Partners, Energy Transfer Equity, Energy Transfer Partners and Biogen are among the stocks discussed here.
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), ETP: 45.34 (+1.58), ETE: 24.69 (+0.90), WPZ: 35.00 (+0.17)
Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices
at The Street - Fri Oct 02, 11:32AM CDT
Rising drug prices are getting increased scrutiny from lawmakers and presidential hopefuls, but here are nine stocks positioned well.
AGN: 268.99 (-3.89), ESRX: 82.57 (+1.27), VRTX: 109.40 (-0.06), WBA: 84.44 (+0.34), PFE: 33.29 (+0.50), ALXN: 164.78 (+4.78), CVS: 101.01 (+1.19), BMY: 60.55 (+0.67), ALKS: 59.98 (+1.48), MS: 32.93 (+0.57)
Pharma Deals in Latin America Continue, Teva to Buy Rimsa
Arpita Dutt - Zacks Investment Research - Fri Oct 02, 9:00AM CDT
Teva (TEVA) joins the league of health care companies expanding their presence in Latin America through acquisitions.
AGN: 268.99 (-3.89), ENDP: 63.14 (-0.96), MYL: 42.23 (-0.62), TEVA: 58.55 (+0.58)
Allergan and Humana Announce Research Partnership to Improve Health Outcomes
PR Newswire - Fri Oct 02, 7:30AM CDT
Allergan plc (NYSE: AGN), a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, to explore new ideas and ways to improve the health and well-being of patients, members and their caregivers.
AGN: 268.99 (-3.89), HUM: 180.92 (+2.02)
Urinary Incontinence - Pipeline Review, H2 2015
M2 - Fri Oct 02, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwlrf3/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Astellas Pharma Inc. - Celogos - Cook MyoSite Incorporated - Evotec AG - FemmePharma Global Healthcare, Inc. - Innovacell Biotechnologie AG - TheraVida, Inc. Drug Profiles - (mirabegron solifenacin succinate) - ASP-2205 - ASP-5633 - Cell Therapy for Urinary Incontinence - ICES-13 - oxybutynin hydrochloride - Prof-003 - RCD-1 - senrebotase - Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - THVD-201 - THVD-202 For more information visit http://www.researchandmarkets.com/research/jwlrf3/urinary
AGN: 268.99 (-3.89)
Allergan wins US FDA approval for JUVEDERM ULTRA XC for lip augmentation
M2 - Fri Oct 02, 6:01AM CDT
Pharmaceutical company Allergan (NYSE:AGN) disclosed on Thursday that it has received approval from the US Food and Drug Administration (FDA) to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21.
AGN: 268.99 (-3.89)
KYBELLA® Injection Wins Allure Magazine "Best of Beauty" Award
PR Newswire - Fri Oct 02, 6:01AM CDT
Allergan, plc (NYSE: AGN) is pleased to announce that KYBELLA® (deoxycholic acid) injection, the first and only FDA-approved injectable treatment for improving the appearance of moderate to severe submental fullness, also known as "double chin," received a "2015 Breakthrough Award" from Allure Magazine. The publication honored KYBELLA®, along with other winners from their annual "Best of Beauty" list, which included hundreds of luxury, mass market and specialty beauty and aesthetic brands, on September 21 at an awards ceremony held at One World Trade Center in New York.
AGN: 268.99 (-3.89)
Markets Close Mixed Ahead Of Jobs Report – Markets This Morning
Dana Blankenhorn - Amigobulls - Fri Oct 02, 5:22AM CDT
Markets closed mixed ahead of US jobs data. Biotech stock recovered from their earlier lows. Jobs data will dictate what happens markets this morning.
NFLX: 108.10 (-0.23), AGN: 268.99 (-3.89), AMZN: 541.94 (+4.46), NBIX: 38.93 (-1.07), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55), MSFT: 46.80 (+0.05), AAPL: 110.78 (-0.53), CELG: 116.98 (+4.79)
Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin
PR Newswire - Thu Oct 01, 8:10AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel prescription products for the medical aesthetics market. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion.
AGN: 268.99 (-3.89)
U.S. FDA Approves JUVEDERM® ULTRA XC for Use in Lips
PR Newswire - Thu Oct 01, 6:01AM CDT
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM® ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM® ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.
AGN: 268.99 (-3.89)
Allergan (AGN) Stock Spiked on Strong Revenue Projection
at The Street - Wed Sep 30, 3:52PM CDT
Allergan (AGN) shares closed trading up nearly 8% after the company updated its fiscal 2015 second half financial expectations.
AGN: 268.99 (-3.89), TEVA: 58.55 (+0.58)
This Is How Big Money Is Made
at The Street - Wed Sep 30, 2:27PM CDT
We lighten up on what we bought when we had courage.
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), ETP: 45.34 (+1.58)
